Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIA
Patent Information
- Authority / Receiving Office
- CN · China
- Current Assignee / Owner
- SANOFI AVENTIS SA
- Publication Date
- 2011-05-11
- Estimated Expiration
- Not applicable · inactive patent
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The present invention relates to novel compounds of formula I which inhibit the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor), their preparation and their use as medicaments. Background technique
[0002] The enzyme TAFIa is generated from the thrombin-activatable fibrinolysis inhibitor zymogen (TAFI) by, for example, thrombin activation. The enzyme TAFI, also known as plasma procarboxypeptidase B, procarboxypeptidase U or procarboxypeptidase R, is a proenzyme similar to carboxypeptidase B (L. Bajzar, Arterioscler. Thromb. Vasc. Biol. 2000, pp. 2511-2518).
[0003] During clot formation, thrombin is produced as the end product of the coagulation cascade, which induces the conversion of soluble plasma fibrinogen into an insoluble fibrin matrix. At the same time, thrombin can activate the endogenous fibrinolysis inhibitor TAFI. Thus, during thrombus formation and lysis, activated TAFI (TAFIa) is generated from the zymogen TAFI b...